Cardio Diagnostics Holdings, Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated December 18, 2023, reports the results of the Annual Meeting of Stockholders held on that date. Cardio Diagnostics Holdings, Inc. is a Delaware corporation with its principal executive offices in Chicago, IL. The company's common stock (CDIO) and redeemable warrants (CDIOW) are listed on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
Of the 18,753,678 shares eligible to vote, 9,794,482 shares (approximately 52%) were present or represented by proxy. Stockholders approved four proposals:
- Proposal 1 (Election of Directors): Seven directors were elected on a plurality basis. All nominees received significant support, with votes "For" ranging from approximately 5.89 million to 5.99 million per nominee.
- Proposal 2 (Reverse Stock Split): Approved. The amendment authorizes a reverse stock split between 1-for-5 and 1-for-40 at the Board's discretion. The amendment will only be filed if the Board deems it necessary within one year. Votes: 7,424,337 For; 2,251,192 Against.
- Proposal 3 (Share Issuance): Approved. This authorizes the future issuance of shares or convertible securities equal to 20% or more of outstanding common stock in non-public transactions, as required by Nasdaq Rule 5635(d). Votes: 5,014,358 For; 1,156,400 Against.
- Proposal 4 (Auditor Ratification): Approved. Prager Metis CPA's LLC was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2023. Votes: 9,065,135 For; 591,235 Against.
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial guidance, outlook, or specific risk factors. The primary contingency noted is the potential implementation of the reverse stock split, which remains at the discretion of the Board of Directors for the next year.
Investor Verification Checklist
- Verify the definitive proxy statement filed on October 27, 2023, for detailed biographies of the elected directors and terms of the reverse stock split.
- Monitor future Board announcements to determine if and when the reverse stock split (1-for-5 to 1-for-40) will be implemented.
- Review upcoming filings for details on any non-public financing transactions executed under the authority of Proposal 3.
- Confirm the final financial statements for the fiscal year ending December 31, 2023, to be audited by Prager Metis CPA's LLC.